Technavio, a leading provider of market research reports, has released its latest study on Tardive Dyskinesia Treatment Market. This report offers a comprehensive analysis of the current market trends, emerging opportunities, and key challenges.
According to Technavio, the global Tardive Dyskinesia (TD) Treatment Market is a segment of the expansive Global Pharmaceuticals Market, which encompasses entities involved in R&D or manufacturing of various drug categories, including generics, non-generics, and veterinary drugs. The healthcare industry's overall size is determined by Technavio through the consolidated revenue generated by pharmaceutical manufacturers and providers, as well as those dealing in equipment, supplies, biotechnology, life sciences tools, and services. The burgeoning Global Pharmaceuticals Market growth can be attributed to several key factors, including the increasing global population aging, with the number of individuals aged 60 and above projected to rise significantly. - The Tardive Dyskinesia Treatment Market is experiencing significant growth, fueled by the Rising cases of mental disorders. Businesses are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Know what is trending in the market - Access a free sample report!
The market size is estimated to grow by USD 632.45 million, at a CAGR of 4.73% during the forecast period. Initiatives to spread awareness regarding treatment of tardive dyskinesia | Growing regulatory approval for treating tardive dyskinesia | Increasing research funding by pharmaceutical companies
For insights on company offerings- Request a sample report!
The North American tardive dyskinesia (TD) treatment market is poised for substantial expansion during the forecast period, driven by escalating healthcare expenditures and a robust healthcare infrastructure. For instance, the US National Health Expenditure data reveals a 2.7% growth to USD4.3 trillion in 2021, representing 18.3% of the GDP. Moreover, private health insurance expenditure on healthcare surged by 5.8% to USD1.1 trillion. With a significant portion of the population diagnosed with schizophrenia, bipolar disorder, schizoaffective disorder, anxiety, or depression, and undergoing antipsychotic treatment, the risk of TD development is high. This market trend underscores the growing demand for effective TD treatments in North America.
Tardive Dyskinesia (TD) is a debilitating neuropsychiatric disorder characterized by involuntary movements of the tongue, eyeballs, lips, and face. It is a common side effect of long-term use of neuroleptic medications, which are commonly prescribed for psychotic disorders, including schizophrenia, bipolar disorder, and depression. TD is also observed in patients with Huntington chorea, Epilepsy, Alzheimer's disease, and Parkinson's disease. The pharmaceutical industry is actively seeking disease-specific novel treatments for TD. Research is focusing on targeting the Vesicular monoamine transporter, which plays a crucial role in the regulation of Dopamine, a neurotransmitter implicated in TD. Neuroactive peptides and Monoamine Oxidase-B Inhibitors are also being explored as potential treatments. TD can manifest as involuntary movements in various parts of the body, including the tongue, lips, and eyes. These movements can significantly impact a patient's quality of life, leading to social isolation, embarrassment, and functional impairment. TD is not limited to neuroleptic disorders; it can also occur with gastrointestinal conditions and other neurological disorders. Antipsychotic drugs and psychotropic drugs are the primary cause of TD. Akathisia, a side effect of neuroleptic medications, is also associated with TD. The striatum, a part of the basal ganglia, is believed to be the primary site of TD pathology. TD is not limited to psychotic disorders; it can also occur in patients with depression, anxiety, schizoaffective disorder, and schizophrenia. Therefore, there is an urgent need for effective TD treatments to improve the lives of millions of affected patients.
Technavio is a global market research company offering comprehensive reports and insights on various industries. Our research helps businesses make informed decisions by providing actionable data and trends. Technavio is based on four simple principles: easy-to-access reports, robust industry coverage, a focus on new and emerging technologies, and competitive pricing. We believe in helping companies and executives become better equipped to make faster, sounder, and more effective decisions. Technavio is one of the most influential market research and advisory firms in the world. We work with business and technology leaders to provide cutting-edge market research and insights to companies.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
